2例伊马替尼治疗是酸性粒细胞增多.pdf

Ann Hematol (2006) 85: 1– 16 DOI 10.1007/s00277-005-1084-7 ORIGINAL ARTICLE Antonia M. S. Müller . Uwe M. Martens . Silke C. Hofmann . Leena Bruckner-Tuderman . Roland Mertelsmann . Michael Lübbert y Imatinib mesylate as a novel treatment option l for hypereosinophilic syndrome: two case reports n and a comprehensive review of the literature o Received: 31 January 2005 / Accepted: 1 July 2005 / Published online: 1 September 2005 # Springer-Verlag 2005 e s . Abstract Hypereosinophilic syndromes (HES) are a het- Keywords Hypereosinophilic syndrome Chronic erogenous group of rare disorders characterized by sustained eosinophilic leukemia . Imatinib mesylate . Novel and otherwise unexplained overproduction of eosinophils treatment options . End organ damage u with organ involvement and consecutive dysfunction. Re- cent reports document the efficacy of imatinib mesylate in a l large proportion of HES patients (65%). Rearrangements in- Introduction volving the platelet-derived growth factor receptor genes a (PDGFRA and PDGFRB), both tyrosine kinase receptors, Hypereosinophilic syndrome (HES) is, by definition, a have been demonstrated to be pathogenetically linked to the condition of sustained hypereosinophilia 1.5×109/l for n dysregulated clonal overproduction of eosinophils. This re- more than 6 months with evidence of organ involvement fined hypothesis has been confirmed by the discover